Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2011 Results
Date:5/5/2011

8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 73214212.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days, through June 3, 2011.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com .

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products, product candidates or partnered products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval fo
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
7. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
8. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
9. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... will support Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... 20 Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, ... of,gastrointestinal and liver diseases, has announced the completion of a,$35.5 ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... Alzheimer,s disease for the quarter ended September 30,2007. ... royalty payments on sales of Memantine by Merz ...
... Rensselaer Polytechnic Institute have demonstrated that liquids embedded ... exposed to electric fields. The finding could lead ... phone displays, and other microscale fluidic devices. , ... for using nanofluids in microscale and nanoscale actuator ...
Cached Biology Technology:Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine 2Strengthening fluids with nanoparticles 2
(Date:7/31/2014)... State University researchers have completed a 20-year study ... Hills prairie at different times of the year. ... late spring time frame has no measurable negative ... have multiple benefits. , The study was conducted ... Prairie Biological Station fire chief, and Joseph Craine, ...
(Date:7/31/2014)... scientists from Spain, France, and the U.S. has ... the oldest definitive member of the tribe Omaliini ... discovery and description were made possible through the ... technique, which allows the detailed study of otherwise ... is described in the journal Annals of ...
(Date:7/31/2014)... German . ... to a sponge that soaks up liquids. Hence, these ... greenhouse gases. However, loading of many MOFs is inhibited ... now report in Nature Communications that the ... This can be prevented by water-free synthesis and storing ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3Free pores for molecule transport 2
... 22, 2010) The National Science Foundation has awarded ... Biological Laboratory $1.7 million to repair and rebuild its ... the pier has played an instrumental role in the ... change, fisheries management and the health of the Chesapeake ...
... reporting the development and successful initial testing of a new ... to be given as nose drops rather than injected. It ... they say. The report appears in ACS, Molecular Pharmaceutics ... note that brain cancer is difficult to treat, partly because ...
... water," which resembles powdered sugar, could provide a new ... greenhouse gas that contributes to global warming, scientists reported ... Society. The powder shows bright promise for a number ... be a greener, more energy-efficient way of jump-starting the ...
Cached Biology News:UMCES Chesapeake Biological Laboratory to rebuild historic research pier 2
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... total protein western blot (WtPAN) ... tissue specific protein expression in ... protein is included in each ... for comparison between different western ...
Biology Products: